| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 144 | 2026 | 309 | 24.510 |
Why?
|
| Cardiac Catheterization | 74 | 2026 | 559 | 14.280 |
Why?
|
| Pulmonary Valve | 25 | 2026 | 102 | 9.760 |
Why?
|
| Heart Valve Prosthesis Implantation | 23 | 2026 | 198 | 8.820 |
Why?
|
| Stents | 34 | 2025 | 564 | 7.630 |
Why?
|
| Heart Valve Prosthesis | 19 | 2026 | 129 | 7.220 |
Why?
|
| Septal Occluder Device | 18 | 2025 | 37 | 6.090 |
Why?
|
| Pulmonary Valve Insufficiency | 14 | 2026 | 48 | 5.640 |
Why?
|
| Heart Defects, Congenital | 37 | 2025 | 910 | 4.850 |
Why?
|
| Heart Septal Defects, Atrial | 12 | 2025 | 58 | 4.610 |
Why?
|
| Prosthesis Design | 32 | 2026 | 356 | 4.420 |
Why?
|
| Pulmonary Artery | 21 | 2025 | 1129 | 4.040 |
Why?
|
| Aortic Coarctation | 10 | 2022 | 78 | 3.620 |
Why?
|
| Treatment Outcome | 119 | 2026 | 11794 | 3.240 |
Why?
|
| Pulmonary Valve Stenosis | 8 | 2026 | 27 | 2.970 |
Why?
|
| Pulmonary Veins | 9 | 2025 | 108 | 2.880 |
Why?
|
| Cardiac Surgical Procedures | 19 | 2021 | 611 | 2.650 |
Why?
|
| Hypoplastic Left Heart Syndrome | 7 | 2025 | 119 | 2.590 |
Why?
|
| Heart Septal Defects, Ventricular | 6 | 2026 | 45 | 2.490 |
Why?
|
| Translocation, Genetic | 15 | 2025 | 120 | 2.300 |
Why?
|
| Humans | 333 | 2026 | 145785 | 2.280 |
Why?
|
| Genomics | 13 | 2026 | 830 | 2.090 |
Why?
|
| Ventricular Outflow Obstruction | 5 | 2023 | 38 | 2.040 |
Why?
|
| Tetralogy of Fallot | 9 | 2025 | 78 | 2.000 |
Why?
|
| Heart Atria | 5 | 2024 | 141 | 1.840 |
Why?
|
| Immunoglobulin Light Chains | 9 | 2026 | 52 | 1.830 |
Why?
|
| Hemodynamics | 27 | 2026 | 1118 | 1.810 |
Why?
|
| Biomarkers, Tumor | 18 | 2025 | 1329 | 1.750 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 18 | 2025 | 699 | 1.750 |
Why?
|
| Chromothripsis | 4 | 2022 | 4 | 1.740 |
Why?
|
| Diphosphonates | 5 | 2013 | 68 | 1.680 |
Why?
|
| Male | 172 | 2026 | 73012 | 1.680 |
Why?
|
| Vascular Fistula | 2 | 2024 | 22 | 1.650 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2025 | 85 | 1.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 1969 | 1.620 |
Why?
|
| Retrospective Studies | 80 | 2026 | 17330 | 1.610 |
Why?
|
| Angioplasty, Balloon | 6 | 2020 | 94 | 1.590 |
Why?
|
| Mitral Valve | 4 | 2025 | 95 | 1.560 |
Why?
|
| Plasma Cells | 9 | 2025 | 80 | 1.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2025 | 390 | 1.490 |
Why?
|
| Ductus Arteriosus, Patent | 9 | 2025 | 52 | 1.480 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2024 | 1450 | 1.480 |
Why?
|
| Infant | 61 | 2026 | 10091 | 1.470 |
Why?
|
| Angiography | 11 | 2021 | 208 | 1.450 |
Why?
|
| Chromosome Aberrations | 15 | 2026 | 166 | 1.430 |
Why?
|
| Ductus Arteriosus | 4 | 2017 | 72 | 1.420 |
Why?
|
| Female | 158 | 2026 | 79045 | 1.400 |
Why?
|
| Bone Density Conservation Agents | 5 | 2013 | 82 | 1.370 |
Why?
|
| Child | 79 | 2025 | 22740 | 1.370 |
Why?
|
| Clodronic Acid | 4 | 2012 | 19 | 1.360 |
Why?
|
| Heart Ventricles | 13 | 2025 | 756 | 1.350 |
Why?
|
| Child, Preschool | 52 | 2025 | 11868 | 1.330 |
Why?
|
| Virtual Reality | 2 | 2024 | 82 | 1.320 |
Why?
|
| Thalidomide | 8 | 2020 | 43 | 1.320 |
Why?
|
| Cardiology | 5 | 2022 | 362 | 1.290 |
Why?
|
| Prognosis | 41 | 2026 | 4330 | 1.280 |
Why?
|
| Stenosis, Pulmonary Vein | 4 | 2025 | 19 | 1.280 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2025 | 67 | 1.270 |
Why?
|
| Genome, Human | 8 | 2025 | 422 | 1.260 |
Why?
|
| Bone Marrow | 5 | 2020 | 307 | 1.250 |
Why?
|
| Imidazoles | 4 | 2012 | 247 | 1.230 |
Why?
|
| Adolescent | 70 | 2025 | 22577 | 1.210 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 4 | 2026 | 10 | 1.180 |
Why?
|
| Echocardiography, Transesophageal | 10 | 2026 | 132 | 1.160 |
Why?
|
| Gene Expression Profiling | 14 | 2025 | 1777 | 1.150 |
Why?
|
| Middle Aged | 89 | 2026 | 36309 | 1.120 |
Why?
|
| Echocardiography | 10 | 2023 | 648 | 1.110 |
Why?
|
| Predictive Value of Tests | 12 | 2025 | 2123 | 1.090 |
Why?
|
| Heart Valve Diseases | 3 | 2019 | 151 | 1.060 |
Why?
|
| Mutation | 22 | 2026 | 4090 | 1.060 |
Why?
|
| Adult | 83 | 2026 | 40882 | 1.040 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2018 | 65 | 1.020 |
Why?
|
| Multimodal Imaging | 4 | 2024 | 129 | 1.010 |
Why?
|
| Prosthesis Failure | 5 | 2025 | 125 | 1.010 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2025 | 68 | 1.000 |
Why?
|
| Amyloid | 3 | 2026 | 96 | 0.990 |
Why?
|
| Pulmonary Atresia | 3 | 2023 | 23 | 0.990 |
Why?
|
| Follow-Up Studies | 30 | 2025 | 5428 | 0.970 |
Why?
|
| Ventricular Function, Left | 4 | 2025 | 544 | 0.970 |
Why?
|
| Genome-Wide Association Study | 15 | 2024 | 1430 | 0.970 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 146 | 0.960 |
Why?
|
| Aged | 77 | 2026 | 26217 | 0.950 |
Why?
|
| Sinus of Valsalva | 1 | 2026 | 11 | 0.950 |
Why?
|
| Radiation Exposure | 3 | 2024 | 63 | 0.950 |
Why?
|
| Coronary Sinus | 1 | 2026 | 9 | 0.950 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2026 | 2399 | 0.950 |
Why?
|
| Hypertension, Pulmonary | 9 | 2023 | 1957 | 0.940 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2025 | 40 | 0.930 |
Why?
|
| Femoral Artery | 3 | 2025 | 190 | 0.930 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2025 | 1150 | 0.920 |
Why?
|
| Young Adult | 40 | 2025 | 14254 | 0.920 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2017 | 228 | 0.920 |
Why?
|
| Gene Dosage | 4 | 2021 | 145 | 0.920 |
Why?
|
| Iatrogenic Disease | 1 | 2026 | 74 | 0.900 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2025 | 20 | 0.890 |
Why?
|
| Cannula | 1 | 2025 | 28 | 0.890 |
Why?
|
| Echocardiography, Doppler | 3 | 2025 | 115 | 0.880 |
Why?
|
| Norwood Procedures | 2 | 2025 | 33 | 0.880 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 120 | 0.880 |
Why?
|
| Thrombosis | 3 | 2025 | 400 | 0.880 |
Why?
|
| Melphalan | 9 | 2025 | 43 | 0.870 |
Why?
|
| United Kingdom | 16 | 2022 | 358 | 0.860 |
Why?
|
| Multidetector Computed Tomography | 1 | 2025 | 40 | 0.860 |
Why?
|
| Amyloidosis | 2 | 2021 | 45 | 0.840 |
Why?
|
| Risk Factors | 42 | 2026 | 10919 | 0.830 |
Why?
|
| Clonal Evolution | 6 | 2021 | 47 | 0.830 |
Why?
|
| Fistula | 1 | 2024 | 49 | 0.830 |
Why?
|
| Time Factors | 31 | 2026 | 7134 | 0.820 |
Why?
|
| Endovascular Procedures | 5 | 2020 | 390 | 0.810 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2024 | 2181 | 0.810 |
Why?
|
| Transplantation, Autologous | 18 | 2025 | 301 | 0.810 |
Why?
|
| Arteriovenous Malformations | 1 | 2024 | 33 | 0.800 |
Why?
|
| Fluoroscopy | 8 | 2024 | 180 | 0.800 |
Why?
|
| Infant, Newborn | 26 | 2025 | 6465 | 0.800 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 243 | 0.800 |
Why?
|
| Mitral Valve Stenosis | 2 | 2016 | 20 | 0.780 |
Why?
|
| Boron Compounds | 6 | 2025 | 29 | 0.780 |
Why?
|
| Postoperative Complications | 10 | 2025 | 2977 | 0.780 |
Why?
|
| Heart-Assist Devices | 3 | 2025 | 568 | 0.780 |
Why?
|
| Smoldering Multiple Myeloma | 6 | 2022 | 9 | 0.770 |
Why?
|
| Antineoplastic Agents | 11 | 2025 | 2219 | 0.770 |
Why?
|
| Pericardial Effusion | 1 | 2023 | 22 | 0.760 |
Why?
|
| Pulmonary Circulation | 7 | 2025 | 430 | 0.750 |
Why?
|
| Glycine | 6 | 2025 | 186 | 0.730 |
Why?
|
| Transcription Factors | 7 | 2024 | 1736 | 0.730 |
Why?
|
| Coronary Vessels | 4 | 2023 | 246 | 0.720 |
Why?
|
| Blood Pressure | 6 | 2021 | 1782 | 0.720 |
Why?
|
| Aorta, Thoracic | 3 | 2023 | 288 | 0.720 |
Why?
|
| Dexamethasone | 17 | 2023 | 365 | 0.700 |
Why?
|
| Survival Rate | 15 | 2021 | 2094 | 0.700 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2013 | 38 | 0.690 |
Why?
|
| DNA-Binding Proteins | 5 | 2024 | 1482 | 0.680 |
Why?
|
| Cyclin D1 | 4 | 2020 | 64 | 0.680 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2021 | 42 | 0.670 |
Why?
|
| Stem Cell Transplantation | 9 | 2023 | 189 | 0.670 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 735 | 0.670 |
Why?
|
| Telomere Homeostasis | 1 | 2021 | 33 | 0.670 |
Why?
|
| Magnetic Resonance Imaging, Cine | 6 | 2025 | 214 | 0.660 |
Why?
|
| Arteriovenous Fistula | 2 | 2024 | 38 | 0.660 |
Why?
|
| Bioprosthesis | 2 | 2020 | 39 | 0.650 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2022 | 248 | 0.650 |
Why?
|
| Radiography, Interventional | 7 | 2019 | 128 | 0.650 |
Why?
|
| Femoral Vein | 3 | 2025 | 38 | 0.650 |
Why?
|
| Heart Diseases | 4 | 2023 | 341 | 0.640 |
Why?
|
| Polytetrafluoroethylene | 2 | 2018 | 23 | 0.640 |
Why?
|
| Aged, 80 and over | 26 | 2026 | 8347 | 0.640 |
Why?
|
| Survival Analysis | 12 | 2021 | 1378 | 0.630 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2022 | 394 | 0.620 |
Why?
|
| Vascular Stiffness | 6 | 2021 | 487 | 0.610 |
Why?
|
| Abnormalities, Multiple | 2 | 2013 | 199 | 0.610 |
Why?
|
| Bortezomib | 9 | 2021 | 54 | 0.610 |
Why?
|
| Aortic Diseases | 3 | 2022 | 125 | 0.610 |
Why?
|
| Oncogenes | 3 | 2021 | 118 | 0.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2022 | 534 | 0.600 |
Why?
|
| Aortography | 3 | 2017 | 52 | 0.590 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2023 | 71 | 0.590 |
Why?
|
| Aorta | 9 | 2020 | 442 | 0.570 |
Why?
|
| Aneurysm, False | 1 | 2019 | 46 | 0.570 |
Why?
|
| Ventricular Function, Right | 6 | 2025 | 297 | 0.570 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2021 | 11 | 0.570 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 224 | 0.570 |
Why?
|
| Stenosis, Pulmonary Artery | 1 | 2018 | 4 | 0.570 |
Why?
|
| Emergencies | 2 | 2019 | 174 | 0.570 |
Why?
|
| Palliative Care | 7 | 2025 | 1022 | 0.560 |
Why?
|
| Remission Induction | 10 | 2021 | 306 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 1505 | 0.560 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 337 | 0.550 |
Why?
|
| Pediatrics | 4 | 2023 | 1125 | 0.550 |
Why?
|
| Hypertension | 2 | 2020 | 1276 | 0.550 |
Why?
|
| Chromium Alloys | 1 | 2018 | 4 | 0.550 |
Why?
|
| Fontan Procedure | 5 | 2020 | 192 | 0.540 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 16 | 0.530 |
Why?
|
| Eczema | 2 | 2018 | 66 | 0.530 |
Why?
|
| Probiotics | 2 | 2018 | 61 | 0.530 |
Why?
|
| Congresses as Topic | 1 | 2019 | 224 | 0.520 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2025 | 86 | 0.520 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 41 | 0.520 |
Why?
|
| Foreign-Body Migration | 2 | 2017 | 33 | 0.510 |
Why?
|
| Factor VIIa | 1 | 2017 | 43 | 0.510 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 750 | 0.510 |
Why?
|
| Hemoptysis | 1 | 2017 | 35 | 0.510 |
Why?
|
| Mutagenesis | 1 | 2018 | 194 | 0.510 |
Why?
|
| Catheter Ablation | 2 | 2023 | 355 | 0.510 |
Why?
|
| Immunologic Factors | 5 | 2023 | 260 | 0.500 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 254 | 0.500 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 549 | 0.500 |
Why?
|
| Whole Genome Sequencing | 7 | 2022 | 178 | 0.490 |
Why?
|
| Diploidy | 3 | 2017 | 17 | 0.490 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 93 | 0.490 |
Why?
|
| Equipment Design | 9 | 2019 | 525 | 0.490 |
Why?
|
| Coronary Angiography | 4 | 2024 | 328 | 0.480 |
Why?
|
| Cyclophosphamide | 9 | 2022 | 272 | 0.480 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2016 | 4 | 0.470 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 521 | 0.470 |
Why?
|
| Transcriptome | 6 | 2025 | 1042 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.460 |
Why?
|
| Imaging, Three-Dimensional | 7 | 2025 | 583 | 0.460 |
Why?
|
| Pain | 1 | 2021 | 791 | 0.460 |
Why?
|
| Videoconferencing | 4 | 2013 | 65 | 0.450 |
Why?
|
| Age Factors | 14 | 2024 | 3346 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2025 | 80 | 0.450 |
Why?
|
| Tertiary Care Centers | 4 | 2017 | 195 | 0.440 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2015 | 17 | 0.430 |
Why?
|
| DNA Mutational Analysis | 5 | 2020 | 410 | 0.430 |
Why?
|
| Recurrence | 9 | 2021 | 1139 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2770 | 0.420 |
Why?
|
| Hemostatic Techniques | 2 | 2011 | 52 | 0.420 |
Why?
|
| Neoplasm, Residual | 6 | 2024 | 143 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2025 | 3916 | 0.410 |
Why?
|
| Telefacsimile | 1 | 2014 | 2 | 0.410 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1062 | 0.400 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 770 | 0.400 |
Why?
|
| Endocarditis | 1 | 2014 | 40 | 0.400 |
Why?
|
| Prospective Studies | 20 | 2026 | 8078 | 0.390 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 3418 | 0.390 |
Why?
|
| Case-Control Studies | 16 | 2024 | 3634 | 0.390 |
Why?
|
| Aortic Stenosis, Supravalvular | 1 | 2013 | 4 | 0.390 |
Why?
|
| Disease Progression | 17 | 2025 | 2865 | 0.390 |
Why?
|
| Electrocardiography | 3 | 2014 | 668 | 0.390 |
Why?
|
| Tomography, Optical Coherence | 3 | 2026 | 270 | 0.390 |
Why?
|
| Embolism, Air | 1 | 2013 | 14 | 0.390 |
Why?
|
| Williams Syndrome | 1 | 2013 | 13 | 0.390 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2013 | 6 | 0.380 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 40 | 0.380 |
Why?
|
| Neoplasm Staging | 9 | 2026 | 1475 | 0.370 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 134 | 0.370 |
Why?
|
| Aneurysm | 1 | 2013 | 37 | 0.370 |
Why?
|
| Infant, Low Birth Weight | 1 | 2013 | 156 | 0.370 |
Why?
|
| Bone Diseases | 2 | 2012 | 61 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 688 | 0.360 |
Why?
|
| Antibodies, Bispecific | 2 | 2025 | 68 | 0.360 |
Why?
|
| Hypertension, Renovascular | 1 | 2011 | 15 | 0.350 |
Why?
|
| Stroke Volume | 6 | 2022 | 655 | 0.350 |
Why?
|
| Absorbable Implants | 2 | 2020 | 38 | 0.350 |
Why?
|
| Kynurenine | 2 | 2024 | 114 | 0.350 |
Why?
|
| Hemorrhage | 3 | 2011 | 823 | 0.350 |
Why?
|
| Renal Artery Obstruction | 1 | 2011 | 30 | 0.350 |
Why?
|
| Immunoglobulins | 4 | 2021 | 163 | 0.340 |
Why?
|
| Renal Artery | 1 | 2011 | 43 | 0.340 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 52 | 0.340 |
Why?
|
| Fractures, Spontaneous | 1 | 2011 | 15 | 0.340 |
Why?
|
| Boronic Acids | 2 | 2011 | 36 | 0.340 |
Why?
|
| Tryptophan | 2 | 2024 | 182 | 0.340 |
Why?
|
| Hospitals, Pediatric | 2 | 2018 | 558 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 971 | 0.330 |
Why?
|
| Precancerous Conditions | 3 | 2025 | 166 | 0.330 |
Why?
|
| Recovery of Function | 4 | 2026 | 716 | 0.330 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 693 | 0.330 |
Why?
|
| Suture Techniques | 1 | 2011 | 137 | 0.320 |
Why?
|
| Pyrazines | 2 | 2011 | 94 | 0.320 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1166 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 102 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 239 | 0.310 |
Why?
|
| Airway Obstruction | 2 | 2023 | 153 | 0.310 |
Why?
|
| Maintenance Chemotherapy | 5 | 2025 | 42 | 0.310 |
Why?
|
| Epigenomics | 3 | 2021 | 117 | 0.310 |
Why?
|
| Platinum | 2 | 2022 | 48 | 0.310 |
Why?
|
| Surgical Instruments | 1 | 2010 | 51 | 0.310 |
Why?
|
| Arterial Pressure | 3 | 2021 | 134 | 0.300 |
Why?
|
| Flow Cytometry | 3 | 2015 | 1165 | 0.300 |
Why?
|
| Hand Deformities, Congenital | 1 | 2009 | 10 | 0.300 |
Why?
|
| Weight Gain | 1 | 2013 | 561 | 0.300 |
Why?
|
| Balloon Valvuloplasty | 3 | 2024 | 5 | 0.290 |
Why?
|
| Cytidine Deaminase | 3 | 2019 | 59 | 0.290 |
Why?
|
| Single-Cell Analysis | 3 | 2025 | 361 | 0.290 |
Why?
|
| Coronary Circulation | 3 | 2022 | 134 | 0.290 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1271 | 0.290 |
Why?
|
| Paraproteins | 2 | 2022 | 3 | 0.280 |
Why?
|
| Spinal Cord Diseases | 1 | 2009 | 42 | 0.280 |
Why?
|
| Ontario | 4 | 2013 | 90 | 0.280 |
Why?
|
| Catheterization | 2 | 2025 | 184 | 0.280 |
Why?
|
| Catheters | 2 | 2023 | 74 | 0.280 |
Why?
|
| Body Weight | 3 | 2025 | 972 | 0.280 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2019 | 328 | 0.280 |
Why?
|
| Climate Change | 2 | 2022 | 177 | 0.270 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 140 | 0.270 |
Why?
|
| Repressor Proteins | 3 | 2016 | 429 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 1582 | 0.270 |
Why?
|
| DNA Copy Number Variations | 4 | 2022 | 188 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 265 | 0.270 |
Why?
|
| B-Lymphocytes | 3 | 2025 | 872 | 0.270 |
Why?
|
| Genotype | 6 | 2019 | 1857 | 0.270 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2021 | 191 | 0.270 |
Why?
|
| B-Cell Maturation Antigen | 2 | 2025 | 17 | 0.270 |
Why?
|
| Genomic Instability | 2 | 2018 | 68 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 2024 | 892 | 0.260 |
Why?
|
| Signal Transduction | 6 | 2025 | 5226 | 0.260 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2019 | 37 | 0.260 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2018 | 76 | 0.250 |
Why?
|
| Evolution, Molecular | 2 | 2021 | 494 | 0.250 |
Why?
|
| Off-Label Use | 2 | 2017 | 51 | 0.250 |
Why?
|
| Systole | 3 | 2022 | 181 | 0.250 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 102 | 0.250 |
Why?
|
| Cardiac Catheters | 2 | 2019 | 16 | 0.250 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 534 | 0.250 |
Why?
|
| Anticoagulants | 2 | 2025 | 748 | 0.250 |
Why?
|
| Myeloma Proteins | 3 | 2020 | 13 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2020 | 23 | 0.240 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 168 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2020 | 59 | 0.240 |
Why?
|
| Heart Failure | 5 | 2021 | 2326 | 0.240 |
Why?
|
| ROC Curve | 2 | 2025 | 618 | 0.240 |
Why?
|
| Bronchi | 2 | 2026 | 263 | 0.240 |
Why?
|
| Body Mass Index | 2 | 2026 | 2447 | 0.240 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 371 | 0.240 |
Why?
|
| Reference Values | 2 | 2024 | 798 | 0.230 |
Why?
|
| Colorado | 3 | 2025 | 4556 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2023 | 668 | 0.230 |
Why?
|
| Exome | 2 | 2017 | 229 | 0.230 |
Why?
|
| Mental Health | 2 | 2022 | 796 | 0.230 |
Why?
|
| Ventricular Pressure | 1 | 2025 | 52 | 0.230 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 45 | 0.230 |
Why?
|
| DNA Methylation | 3 | 2021 | 690 | 0.220 |
Why?
|
| Obesity | 3 | 2026 | 3118 | 0.220 |
Why?
|
| Tracheal Stenosis | 1 | 2026 | 39 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2016 | 169 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 124 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 413 | 0.220 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 712 | 0.220 |
Why?
|
| Oligopeptides | 3 | 2021 | 267 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2025 | 356 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2020 | 672 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 74 | 0.220 |
Why?
|
| Antithrombins | 1 | 2025 | 71 | 0.220 |
Why?
|
| Risk | 4 | 2022 | 923 | 0.220 |
Why?
|
| Tomography | 1 | 2025 | 45 | 0.210 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 442 | 0.210 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2025 | 119 | 0.210 |
Why?
|
| Syndecan-1 | 2 | 2021 | 43 | 0.210 |
Why?
|
| Bronchoscopy | 3 | 2026 | 227 | 0.210 |
Why?
|
| Pulmonary Ventilation | 1 | 2025 | 82 | 0.210 |
Why?
|
| Gene Rearrangement | 2 | 2022 | 156 | 0.210 |
Why?
|
| Protein Folding | 2 | 2026 | 277 | 0.210 |
Why?
|
| Scimitar Syndrome | 1 | 2024 | 10 | 0.210 |
Why?
|
| United States | 9 | 2026 | 16126 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 141 | 0.210 |
Why?
|
| Registries | 6 | 2026 | 2410 | 0.210 |
Why?
|
| North America | 3 | 2022 | 304 | 0.200 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2024 | 14 | 0.200 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 1330 | 0.200 |
Why?
|
| Constriction, Pathologic | 2 | 2022 | 249 | 0.200 |
Why?
|
| Trachea | 1 | 2026 | 258 | 0.200 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.200 |
Why?
|
| Citrulline | 1 | 2024 | 45 | 0.200 |
Why?
|
| Tracheobronchomalacia | 1 | 2023 | 15 | 0.200 |
Why?
|
| Vascular Closure Devices | 1 | 2023 | 6 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2014 | 17 | 0.200 |
Why?
|
| Airway Extubation | 1 | 2024 | 60 | 0.200 |
Why?
|
| Induction Chemotherapy | 2 | 2015 | 88 | 0.200 |
Why?
|
| Electrocoagulation | 1 | 2023 | 35 | 0.190 |
Why?
|
| Alternative Splicing | 2 | 2023 | 248 | 0.190 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 615 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2024 | 6033 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 1925 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2025 | 2064 | 0.190 |
Why?
|
| Ventricular Remodeling | 2 | 2022 | 278 | 0.190 |
Why?
|
| Pericardium | 1 | 2023 | 59 | 0.190 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2021 | 79 | 0.190 |
Why?
|
| Immunoglobulin D | 1 | 2022 | 29 | 0.190 |
Why?
|
| Arginine | 1 | 2024 | 264 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2019 | 900 | 0.180 |
Why?
|
| Tumor Burden | 2 | 2020 | 325 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2023 | 78 | 0.180 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2002 | 16 | 0.180 |
Why?
|
| Thymidylate Synthase | 1 | 2002 | 13 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 198 | 0.180 |
Why?
|
| Radiation Dosage | 1 | 2024 | 193 | 0.180 |
Why?
|
| Models, Genetic | 3 | 2020 | 527 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 883 | 0.180 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2022 | 9 | 0.180 |
Why?
|
| Feasibility Studies | 3 | 2025 | 1115 | 0.180 |
Why?
|
| Thrombolytic Therapy | 2 | 2025 | 164 | 0.180 |
Why?
|
| Incidence | 5 | 2020 | 2934 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2017 | 667 | 0.180 |
Why?
|
| Heart Bypass, Right | 1 | 2022 | 17 | 0.180 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2020 | 219 | 0.180 |
Why?
|
| Drainage | 1 | 2023 | 185 | 0.180 |
Why?
|
| Perfusion Imaging | 2 | 2019 | 66 | 0.180 |
Why?
|
| Amyloidogenic Proteins | 1 | 2021 | 16 | 0.170 |
Why?
|
| Software | 2 | 2025 | 680 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 3 | 2018 | 166 | 0.170 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2022 | 143 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2008 | 995 | 0.170 |
Why?
|
| Clone Cells | 2 | 2021 | 263 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 514 | 0.170 |
Why?
|
| Blood Volume | 2 | 2021 | 65 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 16 | 0.170 |
Why?
|
| Datasets as Topic | 2 | 2020 | 118 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2025 | 697 | 0.170 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 160 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 166 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2021 | 598 | 0.170 |
Why?
|
| Ventricular Function | 1 | 2021 | 53 | 0.170 |
Why?
|
| Transcriptional Elongation Factors | 2 | 2020 | 39 | 0.170 |
Why?
|
| Alleles | 6 | 2021 | 896 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 204 | 0.160 |
Why?
|
| Postoperative Period | 2 | 2022 | 351 | 0.160 |
Why?
|
| Performance-Enhancing Substances | 1 | 2020 | 11 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 54 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 318 | 0.160 |
Why?
|
| Contrast Media | 1 | 2024 | 497 | 0.160 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 95 | 0.160 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2020 | 4 | 0.160 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 267 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2021 | 157 | 0.160 |
Why?
|
| Endothelin-1 | 1 | 2022 | 181 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2017 | 15 | 0.160 |
Why?
|
| London | 2 | 2018 | 46 | 0.160 |
Why?
|
| Bronchial Diseases | 1 | 2020 | 38 | 0.160 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 126 | 0.160 |
Why?
|
| Models, Biological | 2 | 2020 | 1764 | 0.160 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 7 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 46 | 0.160 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 2 | 0.160 |
Why?
|
| Reoperation | 3 | 2018 | 637 | 0.160 |
Why?
|
| Arkansas | 1 | 2020 | 23 | 0.160 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 428 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-maf | 2 | 2020 | 4 | 0.150 |
Why?
|
| Thrombophilia | 1 | 2020 | 89 | 0.150 |
Why?
|
| Heart Function Tests | 1 | 2019 | 59 | 0.150 |
Why?
|
| Device Removal | 3 | 2017 | 142 | 0.150 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 221 | 0.150 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 172 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 21 | 0.150 |
Why?
|
| Point Mutation | 1 | 2020 | 241 | 0.150 |
Why?
|
| Oxygen Consumption | 2 | 2025 | 719 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2020 | 25 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2020 | 99 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2025 | 1368 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2025 | 769 | 0.150 |
Why?
|
| Genes, myc | 1 | 2019 | 51 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 372 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2514 | 0.150 |
Why?
|
| Stress, Mechanical | 5 | 2019 | 494 | 0.150 |
Why?
|
| Genetic Variation | 4 | 2020 | 977 | 0.140 |
Why?
|
| Cyanosis | 2 | 2016 | 18 | 0.140 |
Why?
|
| Aortic Valve | 2 | 2019 | 364 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 783 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 127 | 0.140 |
Why?
|
| Thoracic Injuries | 1 | 2019 | 71 | 0.140 |
Why?
|
| Vascular Access Devices | 1 | 2019 | 30 | 0.140 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 196 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 297 | 0.140 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 81 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2021 | 562 | 0.140 |
Why?
|
| Anxiety | 2 | 2021 | 1122 | 0.140 |
Why?
|
| Blood Proteins | 1 | 2020 | 239 | 0.140 |
Why?
|
| Quantitative Trait Loci | 5 | 2019 | 381 | 0.140 |
Why?
|
| Compressive Strength | 1 | 2018 | 72 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2017 | 194 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1372 | 0.140 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 46 | 0.140 |
Why?
|
| Protein Conformation | 1 | 2021 | 938 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2002 | 409 | 0.140 |
Why?
|
| Research Design | 3 | 2024 | 1139 | 0.140 |
Why?
|
| Phenotype | 5 | 2022 | 3170 | 0.140 |
Why?
|
| Histones | 3 | 2021 | 666 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 52 | 0.140 |
Why?
|
| Codon | 2 | 2017 | 92 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2025 | 3752 | 0.140 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 172 | 0.140 |
Why?
|
| Atrial Septum | 1 | 2018 | 3 | 0.140 |
Why?
|
| Europe | 4 | 2024 | 421 | 0.130 |
Why?
|
| Length of Stay | 2 | 2024 | 1350 | 0.130 |
Why?
|
| China | 1 | 2019 | 274 | 0.130 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 76 | 0.130 |
Why?
|
| Radiation Protection | 1 | 2018 | 41 | 0.130 |
Why?
|
| Biomarkers | 6 | 2024 | 4302 | 0.130 |
Why?
|
| Heart Septal Defects | 1 | 2017 | 12 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 16 | 0.130 |
Why?
|
| Noonan Syndrome | 1 | 2018 | 14 | 0.130 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2017 | 30 | 0.130 |
Why?
|
| Models, Theoretical | 2 | 2018 | 560 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 256 | 0.130 |
Why?
|
| Turner Syndrome | 1 | 2018 | 65 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 28 | 0.130 |
Why?
|
| Malnutrition | 1 | 2019 | 86 | 0.130 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 420 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 335 | 0.130 |
Why?
|
| Pressure | 3 | 2016 | 226 | 0.130 |
Why?
|
| Radiography | 4 | 2016 | 853 | 0.130 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Blood Flow Velocity | 4 | 2020 | 421 | 0.130 |
Why?
|
| Pain Management | 1 | 2021 | 411 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 344 | 0.130 |
Why?
|
| Dilatation | 1 | 2017 | 73 | 0.130 |
Why?
|
| Ireland | 4 | 2019 | 32 | 0.130 |
Why?
|
| Cardiologists | 1 | 2017 | 45 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 392 | 0.130 |
Why?
|
| Pulmonary Atelectasis | 1 | 2016 | 15 | 0.120 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 30 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2021 | 461 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2022 | 475 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2933 | 0.120 |
Why?
|
| Swine | 1 | 2019 | 826 | 0.120 |
Why?
|
| Immunoglobulin A | 2 | 2017 | 214 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 1547 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 562 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 172 | 0.120 |
Why?
|
| Bacteremia | 1 | 2019 | 222 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 209 | 0.120 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2016 | 10 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 63 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 782 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 321 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 435 | 0.120 |
Why?
|
| Mitosis | 1 | 2017 | 193 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 251 | 0.120 |
Why?
|
| Gene Frequency | 1 | 2017 | 489 | 0.120 |
Why?
|
| Syndrome | 2 | 2019 | 381 | 0.120 |
Why?
|
| Observer Variation | 1 | 2017 | 357 | 0.120 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2015 | 4 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 256 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2018 | 385 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2021 | 789 | 0.110 |
Why?
|
| MafB Transcription Factor | 1 | 2015 | 3 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 751 | 0.110 |
Why?
|
| Fluorocarbons | 1 | 2016 | 120 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2013 | 305 | 0.110 |
Why?
|
| Sex Factors | 4 | 2026 | 2110 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 2 | 2007 | 298 | 0.110 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2015 | 47 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 17 | 0.110 |
Why?
|
| Punctures | 2 | 2011 | 41 | 0.110 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 34 | 0.110 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2014 | 8 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2014 | 36 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 172 | 0.110 |
Why?
|
| Tricuspid Atresia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2021 | 680 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 114 | 0.110 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2014 | 7 | 0.110 |
Why?
|
| Publications | 1 | 2015 | 47 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2021 | 1247 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 338 | 0.100 |
Why?
|
| Lung | 2 | 2025 | 4116 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 2000 | 0.100 |
Why?
|
| Bibliometrics | 1 | 2015 | 66 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2010 | 1083 | 0.100 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 154 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 778 | 0.100 |
Why?
|
| Skin Tests | 1 | 2014 | 94 | 0.100 |
Why?
|
| Kidney | 2 | 2020 | 1497 | 0.100 |
Why?
|
| Computer Communication Networks | 1 | 2013 | 32 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 2014 | 116 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2018 | 867 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 892 | 0.100 |
Why?
|
| Foramen Ovale, Patent | 1 | 2013 | 11 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2016 | 252 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 44 | 0.100 |
Why?
|
| Genetic Loci | 3 | 2020 | 267 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 740 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2014 | 193 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 125 | 0.090 |
Why?
|
| Canada | 1 | 2014 | 432 | 0.090 |
Why?
|
| Remote Consultation | 1 | 2013 | 66 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2013 | 69 | 0.090 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2024 | 58 | 0.090 |
Why?
|
| Home Care Services | 2 | 2013 | 284 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2131 | 0.090 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 520 | 0.090 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2012 | 196 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Mothers | 1 | 2018 | 766 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2010 | 788 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2011 | 35 | 0.090 |
Why?
|
| Research | 1 | 2015 | 431 | 0.090 |
Why?
|
| Cystitis | 1 | 2011 | 24 | 0.080 |
Why?
|
| Starch | 1 | 2011 | 22 | 0.080 |
Why?
|
| Bandages | 1 | 2011 | 41 | 0.080 |
Why?
|
| Vincristine | 2 | 2020 | 144 | 0.080 |
Why?
|
| Vital Signs | 2 | 2021 | 46 | 0.080 |
Why?
|
| Saccharomycetales | 1 | 2011 | 29 | 0.080 |
Why?
|
| Mutation Rate | 2 | 2021 | 35 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 2 | 2002 | 141 | 0.080 |
Why?
|
| Proof of Concept Study | 2 | 2021 | 89 | 0.080 |
Why?
|
| Serotonin | 2 | 2024 | 298 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 630 | 0.080 |
Why?
|
| Hypoxia | 3 | 2024 | 1199 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 1437 | 0.080 |
Why?
|
| Hemostatics | 1 | 2011 | 64 | 0.080 |
Why?
|
| Prevalence | 3 | 2026 | 2875 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2011 | 134 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 196 | 0.080 |
Why?
|
| Mycoses | 1 | 2011 | 88 | 0.080 |
Why?
|
| Neutropenia | 1 | 2011 | 154 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 279 | 0.080 |
Why?
|
| Teleradiology | 1 | 2009 | 5 | 0.080 |
Why?
|
| Exercise Test | 1 | 2013 | 630 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2018 | 1202 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2020 | 50 | 0.070 |
Why?
|
| Autografts | 2 | 2020 | 55 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2002 | 195 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 202 | 0.070 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 45 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1752 | 0.070 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 39 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2020 | 403 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 686 | 0.070 |
Why?
|
| Aortic Aneurysm | 1 | 2009 | 70 | 0.070 |
Why?
|
| Electrodes, Implanted | 1 | 2009 | 114 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 868 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4568 | 0.070 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 293 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2009 | 425 | 0.070 |
Why?
|
| Telemedicine | 2 | 2008 | 967 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2011 | 318 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 128 | 0.070 |
Why?
|
| Apoptosis | 1 | 2016 | 2445 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2007 | 20 | 0.070 |
Why?
|
| Pregnancy | 3 | 2018 | 7216 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 79 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 1049 | 0.060 |
Why?
|
| Telephone | 1 | 2008 | 177 | 0.060 |
Why?
|
| Elastic Modulus | 2 | 2019 | 121 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 66 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 1491 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 712 | 0.060 |
Why?
|
| Critical Care | 1 | 2013 | 702 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2012 | 773 | 0.060 |
Why?
|
| Global Health | 2 | 2020 | 403 | 0.060 |
Why?
|
| Asthma | 1 | 2018 | 1797 | 0.060 |
Why?
|
| Materials Testing | 2 | 2019 | 345 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2008 | 179 | 0.060 |
Why?
|
| Chromatin | 2 | 2021 | 553 | 0.060 |
Why?
|
| Protein Binding | 3 | 2017 | 2240 | 0.060 |
Why?
|
| Chromosome Mapping | 2 | 2019 | 507 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 343 | 0.060 |
Why?
|
| Health Personnel | 2 | 2022 | 757 | 0.060 |
Why?
|
| England | 3 | 2013 | 110 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 2028 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 289 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 6085 | 0.060 |
Why?
|
| Logistic Models | 1 | 2010 | 2139 | 0.060 |
Why?
|
| Hirudins | 1 | 2025 | 53 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 48 | 0.050 |
Why?
|
| Cryoelectron Microscopy | 1 | 2026 | 222 | 0.050 |
Why?
|
| Triazines | 1 | 2025 | 49 | 0.050 |
Why?
|
| Proteomics | 2 | 2023 | 1188 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 297 | 0.050 |
Why?
|
| HIV Infections | 1 | 2020 | 3195 | 0.050 |
Why?
|
| Indazoles | 1 | 2025 | 85 | 0.050 |
Why?
|
| Algorithms | 2 | 2025 | 1851 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2024 | 18 | 0.050 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 4 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2025 | 108 | 0.050 |
Why?
|
| Trisomy | 1 | 2025 | 78 | 0.050 |
Why?
|
| Equipment Failure | 2 | 2019 | 115 | 0.050 |
Why?
|
| Stroke | 1 | 2013 | 1271 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2020 | 324 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 286 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2007 | 420 | 0.050 |
Why?
|
| Social Support | 1 | 2008 | 651 | 0.050 |
Why?
|
| Quality of Life | 3 | 2024 | 3211 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2024 | 118 | 0.050 |
Why?
|
| Triazoles | 1 | 2025 | 191 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 26 | 0.050 |
Why?
|
| Anthropometry | 1 | 2024 | 206 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 426 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 981 | 0.050 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 35 | 0.050 |
Why?
|
| Disease Management | 2 | 2020 | 653 | 0.050 |
Why?
|
| Dual Oxidases | 1 | 2023 | 4 | 0.050 |
Why?
|
| Animals | 3 | 2019 | 38106 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2004 | 136 | 0.050 |
Why?
|
| Silicates | 1 | 2023 | 13 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2016 | 124 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 322 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 101 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2002 | 11 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2022 | 9 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2022 | 5 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2002 | 73 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 297 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 472 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2002 | 59 | 0.050 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2002 | 18 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2002 | 13 | 0.040 |
Why?
|
| Cell Count | 1 | 2002 | 319 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 48 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2025 | 481 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2023 | 168 | 0.040 |
Why?
|
| Germinal Center | 1 | 2002 | 64 | 0.040 |
Why?
|
| Replantation | 1 | 2021 | 32 | 0.040 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2021 | 17 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2021 | 6 | 0.040 |
Why?
|
| Sirolimus | 1 | 2023 | 282 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2026 | 1599 | 0.040 |
Why?
|
| Chromosomes | 1 | 2021 | 106 | 0.040 |
Why?
|
| Telomere | 1 | 2024 | 287 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3551 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 25 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2002 | 250 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 80 | 0.040 |
Why?
|
| Spliceosomes | 1 | 2021 | 54 | 0.040 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2021 | 27 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 41 | 0.040 |
Why?
|
| Polydioxanone | 1 | 2020 | 5 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 85 | 0.040 |
Why?
|
| Folic Acid | 1 | 2002 | 198 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 11 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2021 | 66 | 0.040 |
Why?
|
| CpG Islands | 1 | 2021 | 171 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 241 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 343 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1478 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2020 | 54 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 34 | 0.040 |
Why?
|
| Prednisolone | 1 | 2020 | 67 | 0.040 |
Why?
|
| Photoplethysmography | 1 | 2020 | 19 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 193 | 0.040 |
Why?
|
| Histone Code | 1 | 2020 | 39 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2020 | 56 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 149 | 0.040 |
Why?
|
| Smoking | 2 | 2004 | 1477 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 128 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 91 | 0.040 |
Why?
|
| Aminohydrolases | 1 | 2019 | 3 | 0.040 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2019 | 5 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 81 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 150 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2017 | 1300 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 104 | 0.040 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cytosine Deaminase | 1 | 2019 | 15 | 0.040 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2019 | 12 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 59 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 571 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 1043 | 0.040 |
Why?
|
| Parents | 1 | 2008 | 1407 | 0.040 |
Why?
|
| Airway Management | 1 | 2020 | 81 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 194 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 146 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 117 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 118 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2020 | 149 | 0.040 |
Why?
|
| Collateral Circulation | 1 | 2019 | 20 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 284 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 475 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 419 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 563 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 80 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 218 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2020 | 242 | 0.040 |
Why?
|
| Transplantation | 1 | 2019 | 33 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 31 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 79 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 625 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 337 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2018 | 61 | 0.040 |
Why?
|
| Karyotyping | 2 | 2013 | 106 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 508 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 638 | 0.030 |
Why?
|
| Altitude | 1 | 2023 | 463 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2019 | 72 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 450 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 116 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2023 | 620 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 917 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 139 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1512 | 0.030 |
Why?
|
| Quality Control | 1 | 2018 | 161 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 887 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 72 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2018 | 273 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 255 | 0.030 |
Why?
|
| Vascular Resistance | 2 | 2019 | 370 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 309 | 0.030 |
Why?
|
| Poland | 1 | 2018 | 34 | 0.030 |
Why?
|
| Food Supply | 1 | 2019 | 89 | 0.030 |
Why?
|
| Shear Strength | 1 | 2018 | 73 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 122 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 164 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2393 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 411 | 0.030 |
Why?
|
| Body Size | 1 | 2018 | 88 | 0.030 |
Why?
|
| Heart Rate | 2 | 2021 | 856 | 0.030 |
Why?
|
| Physical Chromosome Mapping | 1 | 2017 | 21 | 0.030 |
Why?
|
| Telemetry | 2 | 2008 | 40 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2017 | 179 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 441 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 238 | 0.030 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2017 | 24 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 58 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 322 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 843 | 0.030 |
Why?
|
| Cell Size | 1 | 2017 | 93 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 42 | 0.030 |
Why?
|
| Public Health | 1 | 2022 | 574 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 732 | 0.030 |
Why?
|
| Instillation, Drug | 1 | 2016 | 9 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 1133 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 1105 | 0.030 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2017 | 58 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2020 | 484 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 592 | 0.030 |
Why?
|
| Internet | 2 | 2013 | 693 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 231 | 0.030 |
Why?
|
| Immunoassay | 1 | 2017 | 109 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 62 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 421 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 467 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 2017 | 110 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 72 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 265 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 64 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 328 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 401 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 669 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 30 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 90 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2016 | 130 | 0.030 |
Why?
|
| Health Policy | 1 | 2019 | 400 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 9 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 112 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 536 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 222 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 948 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 18 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 189 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 860 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 733 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 393 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 145 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1662 | 0.020 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 364 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 501 | 0.020 |
Why?
|
| Oxygen | 1 | 2018 | 981 | 0.020 |
Why?
|
| Ligation | 1 | 2013 | 91 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2014 | 90 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 18358 | 0.020 |
Why?
|
| Alloys | 1 | 2013 | 37 | 0.020 |
Why?
|
| Acute Disease | 2 | 2009 | 1036 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 587 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 558 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 337 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 1311 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 697 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 63 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2011 | 78 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 4151 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2968 | 0.020 |
Why?
|
| Hospitals, District | 1 | 2009 | 7 | 0.020 |
Why?
|
| Northern Ireland | 1 | 2009 | 12 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2010 | 88 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2011 | 152 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 528 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2009 | 25 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 29 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 54 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2601 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2017 | 1247 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 643 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 386 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2805 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 740 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 196 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2009 | 211 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 5925 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 777 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2010 | 1038 | 0.010 |
Why?
|
| Asia | 1 | 2005 | 70 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 739 | 0.010 |
Why?
|
| Platelet Count | 1 | 2005 | 94 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 6 | 0.010 |
Why?
|
| International Cooperation | 1 | 2005 | 197 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2005 | 147 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2004 | 117 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 308 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1898 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1973 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 515 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2002 | 11 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 26 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 255 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 404 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 388 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 1001 | 0.010 |
Why?
|
| Phenytoin | 1 | 1970 | 21 | 0.010 |
Why?
|
| Digoxin | 1 | 1970 | 27 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 1970 | 64 | 0.000 |
Why?
|
| Dogs | 1 | 1970 | 478 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1970 | 411 | 0.000 |
Why?
|